Competitive Decoy Receptor Development Service for CAR-T "Off-Signal" Prevention

Online Inquiry

Background Service What We Can Offer Workflow Highlights FAQs Contact

The allogeneic CAR-T field faces persistent challenges, including high attrition rates driven by antibody-mediated rejection and premature "off-signals" from the host immune system. Creative Biolabs' Development of Competitive Decoy Receptors for CAR-T "Off-Signal" Prevention directly addresses these barriers by engineering innovative decoy platforms that shield therapeutic cells from immune elimination. Through molecular traps and atypical scavenger receptor designs, we provide tailored structural evasion tools that block humoral recognition while preserving anti-tumor function.

Introduction

Decoy receptors for CAR‑T are engineered molecular shields, typically transmembrane or soluble decoys, that competitively intercept unwanted immune signals or antigen interactions to prevent premature T‑cell inactivation or off‑tumor recognition. By selectively blocking suppressive cytokines, neutralizing alloantibodies, or outcompeting low‑density antigen engagement on healthy tissues, these decoy systems preserve CAR‑T cell potency while expanding the therapeutic window against solid tumors and allogeneic barriers.

Fig.1 Engineering competitive decoy receptors to prevent CAR‑T off‑signal. (Creative Biolabs Original) Fig.1 Competitive decoy platforms for mitigating CAR‑T off‑target signaling.

Our Service

Creative Biolabs offers a full spectrum of engineering solutions designed to protect therapeutic cells from host humoral immunity. Through the strategic use of competitive decoy receptors, we counteract anti-HLA antibodies and pro-inflammatory cytokines that otherwise drive the premature elimination of donor T cells.

What We Can Offer

We offer a comprehensive suite of competitive decoy receptor platforms, encompassing inhibitory CAR logic gates, membrane‑anchored high‑affinity sinks, and tumor‑microenvironment‑controlled soluble baits, to precisely prevent off‑target toxicity while preserving potent anti‑tumor activity.

Featured services of development of competitive decoy receptors for CAR-T "off-signal" prevention at Creative Biolabs. (Creative Biolabs Original)

Our Service Process

Required Starting Materials:

The specific CAR sequence or TCR-T framework to be modified.
Target antigen specifications.
Preferred viral or non-viral delivery vector requirements.

Key Steps:

Workflow of development of competitive decoy receptors for CAR-T "off-signal" prevention at Creative Biolabs. (Creative Biolabs Original)

Final Deliverables: The deliverables consist of a comprehensive Structural Validation Report, a Functional Potency Dataset, and the Engineered Master Cell Bank.

Key Advantages

Dual-Antigen Precision: Our platform enables precise "NOT" logic gating via inhibitory CAR (iCAR) design, allowing T cells to discriminate between tumor and healthy tissue based on combinatorial antigen signatures rather than single-target expression.
Antigen-Density Discrimination: We leverage high-affinity membrane-bound decoy receptors that function as competitive sinks, enabling tumor-selective activation only when antigen density exceeds the decoy saturation threshold, a critical advantage for targeting solid tumors with heterogeneous antigen expression.
Spatiotemporally Controlled Inhibition: Our soluble decoy systems incorporate tumor-microenvironment-responsive elements such as protease-activated or masked designs, ensuring that competitive inhibition occurs precisely where needed while avoiding systemic sink effects that compromise anti-tumor efficacy.

FAQ

Q1: Will the expression of a decoy receptor impact the primary CAR's killing ability?

A1: No. Our engineering strategy employs orthogonal receptor designs that are structurally and functionally separated from the CAR signaling apparatus, ensuring the decoy does not interfere with activation, cytolytic activity, or proliferative capacity.

Q2: Can these decoy receptors be used for solid tumor CAR-T applications?

A2: Yes. Solid tumors frequently exploit immunosuppressive cytokines such as TGF‑β to dampen T‑cell function. We engineer customized decoy receptors that neutralize these suppressive signals, preserving CAR‑T cell activity within the hostile tumor microenvironment.

Why Choose Us?

We combine expertise in synthetic biology with proven decoy receptor platforms, including iCAR logic gates, membrane‑bound sinks, and tumor‑responsive soluble traps, to deliver tailored solutions that expand the therapeutic window, mitigate off‑tumor toxicity, and accelerate your program toward clinical translation.

Customer Reviews

"Incorporating Creative Biolabs' decoy receptor technology markedly enhanced the persistence of our allogeneic candidates when challenged with patient-derived alloantibodies, with the CD64-based trap delivering consistent binding performance." Dr. Alan S**.

"Applying Creative Biolabs' modified scavenger receptor constructs advanced our insight into counteracting the inflammatory conditions that typically suppress CAR‑T cell activity within the first 72 hours." Prof. Elena M**.

"Integrating the molecular trap into our established CRISPR workflow proved straightforward: we maintained full cytotoxic potency while achieving robust protection against complement‑dependent lysis." Dr. Robert K**.

How to contact us?

For inquiries regarding custom decoy receptor design, platform integration, or partnership opportunities, please contact our scientific team directly. We are prepared to discuss your program goals and provide tailored solutions to advance your CAR‑T candidates toward clinical development.

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.